EP1546310A4 - Immunmodulierende zusammensetzungen, verfahren zu deren herstellung und verwendungen dafür - Google Patents

Immunmodulierende zusammensetzungen, verfahren zu deren herstellung und verwendungen dafür

Info

Publication number
EP1546310A4
EP1546310A4 EP03783854A EP03783854A EP1546310A4 EP 1546310 A4 EP1546310 A4 EP 1546310A4 EP 03783854 A EP03783854 A EP 03783854A EP 03783854 A EP03783854 A EP 03783854A EP 1546310 A4 EP1546310 A4 EP 1546310A4
Authority
EP
European Patent Office
Prior art keywords
immunomodulation
compositions
producing
methods
immunomodulation compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03783854A
Other languages
English (en)
French (fr)
Other versions
EP1546310A2 (de
Inventor
Ranjeny Thomas
Brendan John O'sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of EP1546310A2 publication Critical patent/EP1546310A2/de
Publication of EP1546310A4 publication Critical patent/EP1546310A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03783854A 2002-08-12 2003-08-12 Immunmodulierende zusammensetzungen, verfahren zu deren herstellung und verwendungen dafür Withdrawn EP1546310A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40313102P 2002-08-12 2002-08-12
US403131P 2002-08-12
AU2002953094A AU2002953094A0 (en) 2002-12-04 2002-12-04 Immunomodulating compositions, processes for their production and uses therefor
AU2002953094 2002-12-04
PCT/AU2003/001021 WO2004015056A2 (en) 2002-08-12 2003-08-12 Immunomodulating compositions, processes for their production and uses therefor

Publications (2)

Publication Number Publication Date
EP1546310A2 EP1546310A2 (de) 2005-06-29
EP1546310A4 true EP1546310A4 (de) 2006-05-17

Family

ID=29408816

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03783854A Withdrawn EP1546310A4 (de) 2002-08-12 2003-08-12 Immunmodulierende zusammensetzungen, verfahren zu deren herstellung und verwendungen dafür

Country Status (4)

Country Link
EP (1) EP1546310A4 (de)
AU (1) AU2002953094A0 (de)
CA (1) CA2494675A1 (de)
WO (1) WO2004015056A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1224264T3 (da) * 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
DE102005016234B4 (de) * 2005-04-08 2008-05-15 Tgc Biomics Gmbh Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen
CN101646418B (zh) * 2006-10-12 2013-07-17 昆士兰大学 调节免疫应答的组合物和方法
JP2010505883A (ja) * 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
WO2014141244A1 (en) 2013-03-12 2014-09-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
CN110923206A (zh) * 2018-09-20 2020-03-27 天津贝罗尼生物科技有限公司 一种抗原呈递细胞的调制方法
CN115505625A (zh) * 2022-10-25 2022-12-23 中南大学 一种预测脐血调节性t细胞临床治疗效果的方法
CN118178638B (zh) * 2024-02-02 2025-11-21 中国人民解放军陆军军医大学 二乙基二硫代氨基甲酸钠在制备疫苗佐剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047543A2 (en) * 1999-12-24 2001-07-05 Synovis Limited Activation and inhibition of the immune system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047543A2 (en) * 1999-12-24 2001-07-05 Synovis Limited Activation and inhibition of the immune system

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
GAO J X ET AL: "CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection", IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 98, no. 2, October 1999 (1999-10-01), pages 159 - 170, XP000973593, ISSN: 0019-2805 *
HAAS M ET AL: "Effect of proteasome inhibitors on monocytic IkB-alpha and -beta depletion, NF-kB activation and cytokine production", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 63, no. 3, March 1998 (1998-03-01), pages 395 - 404, XP000857509, ISSN: 0741-5400 *
HOLLANDER G A ET AL: "Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 10, 1996, pages 4994 - 4998, XP002347200, ISSN: 0027-8424 *
INTERNAL MEDICINE JOURNAL, vol. 32, no. suppl., 2002, pages A14, ISSN: 1444-0903 *
INTERNAL MEDICINE JOURNAL, vol. 33, no. Suppl, 2003, pages A5, ISSN: 1444-0903 *
INTERNAL MEDICINE JOURNAL, vol. 33, no. suppl, 2003, pages A6, ISSN: 1444-0903 *
INTERNAL MEDICINE JOURNAL., vol. 32, no. Suppl., 2002, pages A3, ISSN: 1444-0903 *
LEE J-I ET AL: "Cyclosporin A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 68, no. 9, 15 November 1999 (1999-11-15), pages 1255 - 1263, XP000984802, ISSN: 0041-1337 *
MARTIN E ET AL.: "Antigen-specific suppression of a primed immune response by dendritic cells: implications for autoimmune immunotherapy", COMBINED SCIENTIFIC MEETING OF THE NEW ZEALAND RHEUMATOLOGY ASSOCIATION AND THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION WITH THE NEW ZEALAND HEALTH PROFESSIONALS IN RHEUMATOLOGY AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION OF AUSTRALIA, 26 May 2002 (2002-05-26), Christchurch, New Zealand, XP002347198 *
MARTIN E ET AL: "Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10.", IMMUNITY, vol. 18, no. 1, January 2003 (2003-01-01), pages 155 - 167, XP002347203, ISSN: 1074-7613 *
MARTIN E ET AL: "Inhibition of RelB function in dendritic cells induces antigen-specific tolerance in vivo", ANNUAL SCIENTIFIC MEETING OF THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION, 27 May 2001 (2001-05-27), Adelaide, South Australia, Australia, XP002347199 *
O'SULLIVAN B J ET AL: "RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11421 - 11426, XP002347201, ISSN: 0027-8424 *
O'SULLIVAN BJ ET AL: "Maturation and function of human dendritic cells can be controlled by RelB", ANNUAL SCIENTIFIC MEETING OF THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION, 27 May 2001 (2001-05-27), Adelaide, South Australia, Australia, XP002372798 *
PENNA G ET AL: "1alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 164, 2000, pages 2405 - 2411, XP001026351, ISSN: 0022-1767 *
SNAPPER C M ET AL: "B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation of Ig secretion and Ig class switching", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 4, 1996, pages 1537 - 1541, XP002347202, ISSN: 0022-1007 *
THOMPSON A G ET AL: "T cells signaled by NF-kappaB- dendritic cells are sensitized not anergic to subsequent activation", JOURNAL OF IMMUNOLOGY, vol. 173, no. 3, 1 August 2004 (2004-08-01), pages 1671 - 1680, XP002372799, ISSN: 0022-1767 *
THOMPSON AG ET AL: "Keeping T cells at bay: Inhibition of NFkB in dendritic cells", COMBINED SCIENTIFIC MEETING OF THE NEW ZEALAND RHEUMATOLOGY ASSOCIATION AND THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION WITH THE NEW ZEALAND HEALTH PROFESSIONALS IN RHEUMATOLOGY AND THE RHEUMATOLOGY HEALTH PROFESSIONALS ASSOCIATION OF AUSTRALIA, 26 May 2002 (2002-05-26), Christchurch, New Zealand, XP002372797 *
YOSHIMURA S ET AL: "Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 31, no. 6, June 2001 (2001-06-01), pages 1883 - 1893, XP002221236, ISSN: 0014-2980 *
ZHOU L ET AL: "Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine", CLINICAL IMMUNOLOGY, ACADEMIC PRESS,, US, vol. 93, no. 3, December 1999 (1999-12-01), pages 232 - 238, XP002277919, ISSN: 1521-6616 *

Also Published As

Publication number Publication date
CA2494675A1 (en) 2004-02-19
EP1546310A2 (de) 2005-06-29
AU2002953094A0 (en) 2002-12-19
WO2004015056A2 (en) 2004-02-19
WO2004015056A3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
EP1531985A4 (de) THERMISCHE VERBINDUNGS- UND GRENZFLûCHENSYSTEME, HERSTELLUNGSVERFAHREN UND VERWENDUNGEN DAVON
EP1638993A4 (de) Immunmodulierende zusammensetzungen, anwendungen davon und verfahren zu deren herstellung
FR2828408B1 (fr) Procede de formation d'implant
NL1017508A1 (nl) Formatiebehandelingswerkwijze die vervormbare deeltjes gebruikt.
MA27035A1 (fr) Ligands de recepteurs de 5-ht et leurs utilisations
TWI317736B (en) Methods for the production of redox proteins and heteromultimeric-protein-complexes, and related compositions related applications
FR2847770B3 (fr) Composition epaississante pour des sauces et produits similaires
EP1547465A4 (de) Bl tenreduzierungsmittel
EP1624883A4 (de) Zusammensetzungen und verfahren im zusammenhang mit der produktion von erythropoietin
EP1546310A4 (de) Immunmodulierende zusammensetzungen, verfahren zu deren herstellung und verwendungen dafür
EP1623717A4 (de) Zusammensetzung gegen infektionen mit dem rotavirus und herstellungsverfahren dafür
EP1595289A4 (de) Thermische verbindungssysteme, verfahren zur herstellung und verwendungen dafür
KR20050083178A (ko) 전자상품권을 이용한 상거래 방법
ITPD20030151A1 (it) Riduttore di velocita'
EP1389456A4 (de) Kosmetisches operationsverfahren
EP1355548A4 (de) Anzugeinlagestoff und verfahren zur herstellung des anzugs unter verwendung desselben
FR2847999B1 (fr) Logiciel de modelisation d'emboutissage
FR2840305B1 (fr) Procedes d'obtention d'oligo-mannuronates et guluronates, les produits obtenus et leurs utilisations
ITTO20020694A0 (it) Attenuatore d'impatto frontale
FR2833498B3 (fr) Simulateur d'escalier
FR2849858B1 (fr) Composition servant de colle, son procede d'obtention et ses applications.
ITVA20020051A1 (it) Modificatore di reologia per prodotti destinati all'edilizia.
FR2849056B1 (fr) Mannuronane c5-epimerases d'algues brunes, procedes d'obtention et utilisations
FR2854890B1 (fr) Procede de formation d'une liaison carbone-heteroatome
FR2843750B1 (fr) Composes derives d'arylcarbamates, preparation et utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050301

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060330

17Q First examination report despatched

Effective date: 20061204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070417